3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
47
Carcinoma, Non-Small-Cell Lung
14
Neoplasm Metastasis
11
Neoplasms
9
Colorectal Neoplasms
8
Breast Neoplasms
8
Triple Negative Breast Neoplasms
7
Lung Neoplasms
6
Sarcoma
5
Melanoma
4
Esophageal Neoplasms
3
Cholangiocarcinoma
3
Brain Neoplasms
3
Thyroid Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Pancreatic Diseases
2
Gastrointestinal Neoplasms
2
Carcinoma
2
Biliary Tract Neoplasms
2
Advanced Solid Tumors
2
Adenocarcinoma
2
Urinary Bladder Neoplasms
1
Tongue Neoplasms
1
TNBC
1
Solid Tumor
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Interventions
trifluridine tipiracil drug combination
1
reolysin
1
atezolizumab
1
Gemcitabine
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Anal Cancer Metastatic
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT07280377
2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2
Active not recruiting
122 enrolled